Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

I. M. Thompson; C. R. Spence; D. L. Lamm; N. R. Diluzio

doi:10.1097/00000441-198711000-00002

Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

I. M. Thompson, C. R. Spence, D. L. Lamm, N. R. Diluzio

Mays Cancer Center

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

Original language	English (US)
Pages (from-to)	294-300
Number of pages	7
Journal	American Journal of the Medical Sciences
Volume	294
Issue number	5
DOIs	https://doi.org/10.1097/00000441-198711000-00002
State	Published - Jan 1 1987

Fingerprint

ASJC Scopus subject areas

Medicine(all)

Cite this

Thompson, I. M., Spence, C. R., Lamm, D. L., & Diluzio, N. R. (1987). Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. American Journal of the Medical Sciences, 294(5), 294-300. https://doi.org/10.1097/00000441-198711000-00002

@article{71d285f88d594854851df8644913bed8,

title = "Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide",

abstract = "Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.",

author = "Thompson, {I. M.} and Spence, {C. R.} and Lamm, {D. L.} and Diluzio, {N. R.}",

year = "1987",

month = jan

day = "1",

doi = "10.1097/00000441-198711000-00002",

language = "English (US)",

volume = "294",

pages = "294--300",

journal = "American Journal of the Medical Sciences",

issn = "0002-9629",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide

AU - Thompson, I. M.

AU - Spence, C. R.

AU - Lamm, D. L.

AU - Diluzio, N. R.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

AB - Recent evidence suggests a role for both immunotherapy and chemotherapy in the treatment of transitional cell carcinoma. Glucan, a derivative of the cell wall of Saccharomyces cerevisiae and a potent immunostimulant, was used in combination with cyclophosphamide for treatment of implanted murine transitional cell carcinoma (MBT 2). Cyclophosphamide prevented tumor appearance when tumor burden was low and decreased tumor growth rate in larger tumor volumes, but was unable to eradicate established tumors. Glucan did not reduce tumor incidence but decreased animal mortality. These experimental observations may correlate well with clinical evidence and suggest future clinical use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=0023619601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023619601&partnerID=8YFLogxK

U2 - 10.1097/00000441-198711000-00002

DO - 10.1097/00000441-198711000-00002

M3 - Article

C2 - 3425579

AN - SCOPUS:0023619601

VL - 294

SP - 294

EP - 300

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 5

ER -

Access to Document

10.1097/00000441-198711000-00002